Lung Involvement in Primary Sjögren's Syndrome-An Under-Diagnosed Entity

Georgios Sogkas; Stefanie Hirsch; Karen Maria Olsson; Jan B Hinrichs; Thea Thiele; Tabea Seeliger; Thomas Skripuletz; Reinhold Ernst Schmidt; Torsten Witte; Alexandra Jablonka; Diana Ernst

doi:10.3389/fmed.2020.00332

Lung Involvement in Primary Sjögren's Syndrome-An Under-Diagnosed Entity

Front Med (Lausanne). 2020 Jul 16:7:332. doi: 10.3389/fmed.2020.00332. eCollection 2020.

Authors

Affiliations

¹ Department of Immunology and Rheumatology, Medical School Hannover, Hanover, Germany.
² Department of Respiratory Medicine, Hannover Medical School, Hanover, Germany.
³ BREATH German Centre for Lung Research (DZL), Hanover, Germany.
⁴ Department of Diagnostic and Interventional Radiology, Hannover Medical School, Hanover, Germany.
⁵ Department of Neurology, Hannover Medical School, Hanover, Germany.

Abstract

Interstitial lung disease (ILD) represents a frequent extra-glandular manifestation of primary Sjögren's Syndrome (pSS). Limited published data regarding phenotyping and treatment exists. Advances in managing specific ILD phenotypes have not been comprehensively explored in patients with coexisting pSS. This retrospective study aimed to phenotype lung diseases occurring in a well-described pSS-ILD cohort and describe treatment course and outcomes. Between April 2018 and February 2020, all pSS patients attending our Outpatient clinic were screened for possible lung involvement. Clinical, laboratory and high-resolution computed tomography (HRCT) findings were analyzed. Patients were classified according to HRCT findings into five groups: usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), desquamative interstitial pneumonia (DIP), combined pulmonary fibrosis and emphysema (CPFE), and non-specific-ILD. Lung involvement was confirmed in 31/268 pSS patients (13%). One-third (10/31) of pSS-ILD patients were Ro/SSA antibody negative. ILD at pSS diagnosis was present in 19/31 (61%) patients. The commonest phenotype was UIP n = 13 (43%), followed by NSIP n = 9 (29%), DIP n = 2 (6 %), CPFE n = 2 (6 %), and non-specific-ILD n = 5 (16%). Forced vital capacity (FVC) and carbon monoxide diffusion capacity (D_LCO) appeared lower in UIP and DIP, without reaching a significant difference. Treatment focused universally on intensified immunosuppression, with 13/31 patients (42%) receiving cyclophosphamide. No anti-fibrotic treatments were used. Median follow-up was 38.2 [12.4-119.6] months. Lung involvement in pSS is heterogeneous. Better phenotyping and tailored treatment may improve outcomes and requires further evaluation in larger prospective studies.

Keywords: ESSDAI—EULAR Sjögren's Syndrome Disease Activity Index; Sjögren's Syndrome (SS); interstitial lung disease (ILD); lung fibrosis; sicca syndrome.